AJANTPHARM · Healthcare
Ajanta Pharmaceuticals Ltd. reported revenue of ₹1,303 cr for April to June 2025, +13.8% on the year and +11.4% on the quarter. It is the highest quarterly revenue in the last 9 quarters on record. Over the last four quarters revenue comes to ₹4,806 cr, +10.9% on the four before.
Operating profit (EBITDA) was ₹351 cr, a margin of 26.9%, −188 bps on the year and +155 bps on the quarter. Over the last 8 quarters the margin has ranged from 25.4% to 28.8%, averaging 27.3%. Operating costs grew +16.8%, faster than revenue at +13.8%, so operating profit grew less than sales.
Net profit was ₹255 cr, +3.7% on the year and +13.3% on the quarter, with earnings per share of ₹20.44. Profit before other income, one-offs and tax grew 3.0%, so the profit growth came from the business itself. The tax rate of 23% is in line with its recent average. Profit over the last four quarters totals ₹929 cr, +8.8% on the four before.
On earnings per share of ₹74.44 over the last four quarters, the stock at ₹3,320.10 trades at 44.6 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Operating margin slipped on the year.
EBITDA margin 26.9%, −188 bps on the year (+155 bps on the quarter).
Source: Quarterly statements
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,028 cr | ₹1,105 cr | ₹1,054 cr | ₹1,145 cr | ₹1,187 cr | ₹1,146 cr | ₹1,170 cr | ₹1,303 cr | ₹1,354 cr | ₹1,375 cr | ₹1,422 cr | ₹1,626 cr |
| YoY | — | — | — | +12% | +15% | +4% | +11% | +14% | +14% | +20% | +22% | +25% |
| EBITDA margin | 28.3% | 28.4% | 26.4% | 28.8% | 26.2% | 28.0% | 25.4% | 26.9% | 24.2% | 27.8% | 23.4% | 26.1% |
| Other income, % of PBT | 8% | 5% | 13% | 8% | 7% | 10% | 7% | 8% | 17% | 7% | 18% | 16% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% |
| Net profit | ₹195 cr | ₹210 cr | ₹203 cr | ₹246 cr | ₹216 cr | ₹233 cr | ₹225 cr | ₹255 cr | ₹260 cr | ₹274 cr | ₹267 cr | ₹334 cr |
| YoY | — | — | — | +18% | +11% | +11% | +11% | +4% | +20% | +18% | +19% | +31% |
| Core profit YoY | — | — | — | +25% | +6% | 0% | +4% | +3% | +4% | +21% | +14% | +23% |
| EPS | ₹15.24 | ₹16.39 | ₹15.82 | ₹19.68 | ₹17.33 | ₹18.64 | ₹18.03 | ₹20.44 | ₹20.83 | ₹21.91 | ₹21.35 | ₹26.75 |
| Flags | · | · | · | ✓ | ✓ | ✓ | ✓ | ✓ | 1 | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Ajanta Pharmaceuticals Ltd. reported revenue of ₹1,303 cr (+13.8% on the year) and net profit of ₹255 cr (+3.7% on the year) for April to June 2025.
Profit before other income, exceptional items and tax moved +3.0% on the year, against +3.7% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.